Condition: Generalized Myasthenia Gravis · gMG · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Washington D.C., District of Columbia, United States | Recruiting |
| Research Site | Norfolk, Virginia, United States | Recruiting |
| Research Site | Joinville, Brazil | Recruiting |
| Research Site | Salvador, Brazil | Recruiting |
| Research Site | São José do Rio Preto, Brazil | Recruiting |
| Research Site | São Paulo, Brazil | Recruiting |
| Research Site | São Paulo, Brazil | Recruiting |
| Research Site | Saitama-Shi, Japan | Recruiting |
| Research Site | Bydgoszcz, Poland | Withdrawn |
| Research Site | Lodz, Poland | Withdrawn |
| Research Site | Warsaw, Poland | Recruiting |
| Research Site | New Taipei City, Taiwan | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06607627